Project 34

Real-life evaluation of ticagrelor and prasugrel in chronic coronary syndrome as a second antiplatelet agent

  • Project's holder

    Dr Pierre Deharo

  • Promoter

    Association France PCI

  • Contact

    pierre.deharo@ap-hm.fr

  • Funding

    Non

  • Sample data used

    Earliest date -2023

  • Project progress

    In progress

Project summary

CONTEXT

Ticagrelor and Prasugrel are currently recommended in ACS only. A place was opened for them in the SCC but reserved for the most complex cases with a 2b recommendation. Indeed, the side effects of Ticagrelor and Prasugrel can be a problem in CTS (mainly hemorrhagic)

In current practice we see the use of these drugs as first-line treatment in CTS with /- a de-escalation strategy. Also, the evaluation of these therapies in CTS versus Clopidogrel appears relevant.


GOALS

Demonstrate the non-inferiority of the use of Ticagrelor or Prasugrel versus Clopidogrel as a second antiplatelet agent in angioplasties for SCC.


METHODOLOGY

Non-inferiority on a composite criterion: MACE (stroke, coronary reintervention, heart attack, death) bleeding BARC 2 to 5.

Information patients
Share by: